Ivig

Authors: Prof. Dr. med. Peter Altmeyer, Dr. med. Gustav Lohse

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Intravenous therapy with human immunoglobulins.

Indication
This section has been translated automatically.

For the indications listed here, there are guideline recommendations with varying degrees of evidence.

Dosage and method of use
This section has been translated automatically.

0,2-1,0 (up to 2,0 g) g/kg bw i.v. over several days (guideline standard dosage: 2g/kg bw over 2-5 days).

Undesirable effects
This section has been translated automatically.

Preparations
This section has been translated automatically.

Intratect, Pentaglobin

Literature
This section has been translated automatically.

  1. Ahmed AR et al (2007) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355: 1772-1779
  2. Lemm G (2002) Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 59(12 Suppl 6): S28-32
  3. Sami N et al (2002) Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105: 192-198
  4. Samuelsson A et al (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486
  5. Simon HU, Spath PJ (2003) IVIG - mechanisms of action. Allergy 58: 543-552
  6. Schanz S et al (2008) Response of dystrophic calicification to intravenous immunoglobulin. Arch Dermatol 144: 585-587
  7. Schwörer CV(2015) Guidelines for the use of IVIG in dermatology. derm 21:233
  8. Topf S et al. (2007) Significant improvement of a scleromyxedema Arndt-Gottron by high-dose intravenous immunoglobulins. Dermatologist 58: 525-528

Authors

Last updated on: 29.10.2020